Use of fas ligand to suppress lymphocyte-mediated immune responses
CA 2189778 C · Owner: Duke, Richard C. · Inventors: Bellgrau, Donald; Duke, Richard C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Soluble mouse and human Fas ligand polypeptides and methods for inhibitng T-lymphocyte-mediated immune responses including, those directed against autologous and/or heterologous tissues e g. by a recipient mammal of a transplanted tissue by providing the recipient, mammal with Fas ligand. The Fas ligand may be provided to the recipient mammal by a variety of means,including by direct administration of the Fas ligand or by providing the gene encoding the Fas ligand to a subject such that Fas ligand is synthesized by the subject.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 26, 1995 and granted September 25, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 26, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 26, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.